Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Thursday that the European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) for its chikungunya vaccine, CHIKV VLP.
This initiates the EMA's centralised review under accelerated assessment, potentially supporting approval of the vaccine by the European Commission in the first half of 2025.
The company also submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in June 2024, targeting a potential US approval in the same timeframe.
IgGenix presents IGNX001 data at 2024 ASCIA
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial